AVANIR PHARMACEUTICALS, INC CL A
AVNR
AVNR was delisted on the 12th of January, 2015.
101 hedge funds and large institutions have $350M invested in AVANIR PHARMACEUTICALS, INC CL A in 2013 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 37 increasing their positions, 34 reducing their positions, and 23 closing their positions.
211% more call options, than puts
Call options by funds: $15.7M | Put options by funds: $5.04M
9% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 34
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6% less funds holding
Funds holding: 108 → 101 (-7)
22% less capital invested
Capital invested by funds: $449M → $350M (-$99.4M)
30% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$14.1M |
| 2 |
State Street
Boston,
Massachusetts
|
+$13.4M |
| 3 |
Millennium Management
New York
|
+$9.17M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
+$4.13M |
| 5 |
Goldman Sachs
New York
|
+$4.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$13.1M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$10.3M |
| 3 |
O
OrbiMed
New York
|
-$7.88M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$7.22M |
| 5 |
AG
Artal Group
Luxembourg
|
-$4.54M |
AVNR Hedge Fund Activity: Q4 2013 in Review
101 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in AVANIR PHARMACEUTICALS, INC CL A (AVNR) for Q4 2013, worth a combined $350M — down 22% from $449M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of AVNR and 16 opened new positions — a net loss of 7 holders — while 34 trimmed existing stakes and 37 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $14.1M. The largest seller was Fidelity Investments, cutting an estimated $13.1M.
- 101 institutional investors held AVANIR PHARMACEUTICALS, INC CL A (AVNR) as of Q4 2013, down from 108 in Q3 2013.
- Funds reported $350M of AVANIR PHARMACEUTICALS, INC CL A stock for Q4 2013, down 22% quarter-over-quarter.
- 16 funds opened new AVANIR PHARMACEUTICALS, INC CL A positions in Q4 2013 and 23 closed out, a net change of -7 holders.
- The largest AVANIR PHARMACEUTICALS, INC CL A buyer in Q4 2013 was T. Rowe Price Associates, an estimated $14.1M added.
- The largest AVANIR PHARMACEUTICALS, INC CL A seller in Q4 2013 was Fidelity Investments, an estimated $13.1M sold.
Based on aggregated 13F filings for Q4 2013.